Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label Study of Bortezomib Following Nonmyeloablative Allogeneic Stem Cell Transplant in Patients With High-risk Multiple Myeloma

NCT02308280 is registered in ClinicalTrials.gov with Maisonneuve-Rosemont Hospital as lead sponsor.

NCT NCT02308280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02308280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label Study of Bortezomib Following Nonmyeloablative Allogeneic Stem Cell Transplant in Patients With High-risk Multiple Myeloma
Lead sponsor
Maisonneuve-Rosemont Hospital
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2014
Completion date
September 27, 2023
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk cancer, multiple myeloma